Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 122

Similar articles for PubMed (Select 23363074)

1.

1p/19q testing has no significance in the workup of glioblastomas.

Clark KH, Villano JL, Nikiforova MN, Hamilton RL, Horbinski C.

Neuropathol Appl Neurobiol. 2013 Oct;39(6):706-17. doi: 10.1111/nan.12031.

2.

Alpha internexin expression related with molecular characteristics in adult glioblastoma and oligodendroglioma.

Suh JH, Park CK, Park SH.

J Korean Med Sci. 2013 Apr;28(4):593-601. doi: 10.3346/jkms.2013.28.4.593. Epub 2013 Mar 27.

3.

Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.

Jha P, Agarwal S, Pathak P, Srivastava A, Suri V, Sharma MC, Chosdol K, Srivastava T, Gupta D, Gupta A, Suri A, Sarkar C.

Cancer Genet Cytogenet. 2010 Apr 15;198(2):126-34. doi: 10.1016/j.cancergencyto.2009.12.018.

PMID:
20362227
4.

The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

Horbinski C, Nikiforova MN, Hobbs J, Bortoluzzi S, Cieply K, Dacic S, Hamilton RL.

J Neuropathol Exp Neurol. 2012 Jan;71(1):73-82. doi: 10.1097/NEN.0b013e318240fa65.

5.

Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis.

Pinto LW, Araújo MB, Vettore AL, Wernersbach L, Leite AC, Chimelli LM, Soares FA.

Virchows Arch. 2008 May;452(5):481-90. doi: 10.1007/s00428-007-0562-9.

PMID:
18351387
6.

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.

J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17.

PMID:
23681562
7.

Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms.

Singh VY, Chacko G, Chacko AG, Rajshekhar V.

Neurol India. 2014 Jan-Feb;62(1):32-6. doi: 10.4103/0028-3886.128275. Erratum in: Neurol India. 2014 Mar-Apr;62(2):191.

9.

Prognostic stratification of patients with anaplastic gliomas according to genetic profile.

Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J, Delattre JY, Sanson M.

Cancer. 2006 Oct 15;107(8):1891-7.

10.

Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.

Alentorn A, van Thuijl HF, Marie Y, Alshehhi H, Carpentier C, Boisselier B, Laigle-Donadey F, Mokhtari K, Scheinin I, Wesseling P, Ylstra B, Capelle L, Hoang-Xuan K, Sanson M, Delattre JY, Reijneveld JC, Idbaih A.

Neuro Oncol. 2014 Mar;16(3):400-8. doi: 10.1093/neuonc/not227. Epub 2013 Dec 12.

11.

Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.

Ferrer-Luna R, Mata M, Núñez L, Calvar J, Dasí F, Arias E, Piquer J, Cerdá-Nicolás M, Taratuto AL, Sevlever G, Celda B, Martinetto H.

J Neurooncol. 2009 Dec;95(3):343-54. doi: 10.1007/s11060-009-9944-y. Epub 2009 Jul 12.

PMID:
19597701
12.

Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status?

Campbell BA, Horsman DE, Maguire J, Young S, Curman D, Ma R, Thiessen B.

J Neurooncol. 2008 Aug;89(1):37-45. doi: 10.1007/s11060-008-9597-2. Epub 2008 May 6.

PMID:
18458822
13.

Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.

Jesionek-Kupnicka D, Szybka M, Potemski P, Kulczycka-Wojdala D, Jaskólski D, Bieńkowski M, Skowroński W, Papierz W, Kordek R, Zawlik I.

Pol J Pathol. 2013 Dec;64(4):268-75.

PMID:
24375041
14.

Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas.

Lass U, Hartmann C, Capper D, Herold-Mende C, von Deimling A, Meiboom M, Mueller W.

Brain Pathol. 2013 May;23(3):311-8. doi: 10.1111/bpa.12003. Epub 2012 Nov 29.

PMID:
23107103
15.

Molecular genetic alterations in glioblastomas with oligodendroglial component.

Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U.

Acta Neuropathol. 2001 Apr;101(4):311-20.

PMID:
11355302
16.

Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.

Franco-Hernández C, Martínez-Glez V, de Campos JM, Isla A, Vaquero J, Gutiérrez M, Casartelli C, Rey JA.

Cancer Genet Cytogenet. 2009 Apr 15;190(2):93-6. doi: 10.1016/j.cancergencyto.2008.09.017.

PMID:
19380026
17.

[Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors].

Yao K, Duan Z, Hu Z, Bian Y, Qi X.

Zhonghua Bing Li Xue Za Zhi. 2014 Oct;43(10):663-7. Chinese.

PMID:
25567591
18.

[Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].

Born PW, Broholm H, Laursen H.

Ugeskr Laeger. 2006 Oct 30;168(44):3813-6. Danish.

PMID:
17118240
19.

[Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].

Huang L, Jiang T, Yuan F, Li GL, Xu LX, Cui Y.

Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):752-8. Chinese.

PMID:
22335907
20.

Genetically heterogeneous glioblastoma recurring with disappearance of 1p/19q losses: case report.

Ito M, Wakabayashi T, Natsume A, Hatano H, Fujii M, Yoshida J.

Neurosurgery. 2007 Jul;61(1):E168-9; discussion E169.

PMID:
17621007
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk